Soligenix’s Dusquetide Granted European Patent for Use in Oral Mucositis
Soligenix, Inc. (Nasdaq: SNGX) has been granted a patent by the European Patent Office entitled “Novel Peptides and Analogs for Use in the Treatment of Oral Mucositis”.
This granted patent builds on similar intellectual property issued in the United States, New Zealand, Japan, Australia and Singapore, as well as many pending patent applications in other jurisdictions worldwide.
Highlights
Dusquetide is the active ingredient in Soligenix’s SGX942. Soligenix has previously demonstrated the safety and efficacy of SGX942 in Phase 1 and 2 clinical trials.
The company is pursuing broad patent coverage for its dusquetide technology, first with composition of matter claims followed by therapeutic use claims in oral mucositis.
Mucositis describes the damage done to the mucosa by anticancer therapies. It affects approximately 500,000 people in the US per year and occurs in 40% of patients receiving chemotherapy.
Oral mucositis remains an area of unmet medical need.
About Soligenix, Inc.
Soligenix is a late-stage biopharmaceutical company developing and commercializing products to treat rare diseases where there is an unmet medical need. The company’s Specialized BioTherapeutics business segment is moving toward potential commercialization of HyBryte™ (SGX301 or synthetic hypericin) for the treatment of cutaneous T-cell lymphoma (CTCL). Soligenix’s development programs also include synthetic hypericin (SGX302) as a potential treatment for psoriasis and dusquetide (SGX942) for the treatment of inflammatory diseases. Soligenix’s Public Health Solutions business segment includes active development programs for RiVax®, a ricin toxin vaccine candidate, as well as vaccine programs targeting filoviruses and CiVax™, a vaccine candidate for COVID-19.
